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1. Introduction 
Probiotics are live microorganisms that confer health benefits to the host when administered 
in adequate amounts. In the last decades there has been a great interest from food and 
pharmaceutical industries to develop products containing probiotics due to the great 
demands of healthy foods and alternatives to conventional chemotherapy.  
Although the great bulk of evidence concerns lactobacilli and bifidobacteria, since they are 
members of the resident microbiota in the gastrointestinal tract, other less conventional genera 
like Saccharomyces, Streptococcus, Enterococcus, Pediococcus, Leuconostoc  and Propionibacterium 
have also been considered.  
The genus Propionibacterium has been historically divided, based on habitat of origin, into 
“dairy” and “cutaneous” microorganisms which mainly inhabit dairy/silage environments 
and the skin/intestine of human and animals, respectively. Dairy propionibacteria are 
generally recognized as safe microorganisms whereas members of the cutaneous group 
have shown to be opportunistic pathogens in compromised hosts. In consequence, the 
economic relevance of propionibacteria derives mainly from the industrial application of 
dairy species as cheese starters and as biological producers of propionic acid and other 
metabolites like exopolysaccharides and bacteriocins to be used as thickeners and foods 
preservers, respectively.  
However, the ability of dairy propionibacteria to improve the health of humans and animals 
by being used as dietary microbial adjuncts has been extensively investigated. In this sense, 
our research group has been studying for the last two decades the probiotic properties of 
dairy propionibacteria isolated from different ecological niches. In the present article the 
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current evidences supporting the potential of dairy propionibacteria to be used as probiotics 
are reviewed focusing in a less studied mechanism such as the protection of the intestinal 
mucosa by the binding of dietary toxic compounds.  
Nowadays there are clear evidences that propionibacteria used alone or combined with 
other microorganisms can exert beneficial effects in the host. Dairy propionibacteria have 
proven to posses many promising properties such as the production of nutraceuticals like 
vitamin B2, B12, K and conjugated linoleic acid, and their health promoting effects could be 
attributed to one or more of the following modes of action: i) influence on gut microbial 
composition and exclusion of pathogens; ii) modulation of the metabolic activities of the 
microbiota and host, and iii) immunomodulation. The most documented probiotic effects for 
propionibacteria within these categories include: bifidogenic effect in the human gut, 
improvement of nutrients utilization, hypocholesterolemic effect and anticarcinogenic 
potential immune system stimulation.  
Different studies have also described the ability of dairy propionibacteria to bind and 
remove toxic compounds from different environments such as the gut and food. Some of 
them have focused in the removal of mycotoxins, like Aflatoxin B and Fusarium sp. 
toxins by in vitro, ex vivo and in vivo assays whereas others have reported the binding of 
cyanotoxins and some heavy metals like cadmium and lead. It has been proposed that 
probiotic microorganisms may reduce by binding, the availability of free toxic 
compounds within the intestinal tract which reduces in turn, their negative effects. In 
this respect, in recent years we have been investigating the potential of dairy 
propionibacteria to protect the intestinal mucosa from the toxic and antinutritional 
effects of some common dietary substances like the plant lectins from the Leguminosae 
family. By in vitro and in vivo studies we have determined that certain strains are able to 
bind and remove different dietary lectins from media, preventing their cytotoxic effects 
on intestinal epithelial cells. Daily ingestion of P. acidipropionici CRL 1198, a dairy strain 
studied in our laboratory, at the same time than concanavalin A prevented the 
deleterious effects caused by this lectin on some morphological and physiological 
parameters related to intestinal functionality in mice. Propionibacteria reduced the 
incidence of colonic lesions, the enlargement of organs, the disruption of brush border 
membranes and the decrease of their disaccharidase activities. Since consumption of 
suitable propionibacteria may be an effective tool to avoid lectin-epithelia interactions, 
further investigations on their potential as probiotic detoxifying agents are actually 
ongoing  
With regard to animals’ health it has been reported that dairy propionibacteria directly fed 
to farm animals increased weight gain, food efficiency and health of many animals like 
chickens, laying hens, piglets and cows. With a wider insight, propionibacteria may be 
assayed as probiotics for other ruminants like goats and sheep since their milk-derived 
products are highly appreciated by consumers.  
It should be emphasized that much of the health benefits described above could be 
related to the ability of propionibacteria to remain in high numbers in the 
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gastrointestinal tract by surviving the adverse environmental conditions and adhering to 
the intestinal mucosa. 
On the basis of the GRAS status of dairy propionibacteria and the positive results obtained 
by us and other authors, further studies are encouraged in order to select the appropriate 
strains for developing new functional foods that include these bacteria for human and 
animal nutrition.   
2. The genus propionibacterium 
2.1. General features and taxonomy 
Propionibacteria are Gram positive, catalase positive, high G+C%, non spore forming and 
non motile pleomorphic bacteria [1, 2]. In general, microorganisms of the genus 
Propionibacterium are anaerobic to slightly aerotolerant and morphologically 
heterogeneous including rod-shaped and filamentous branched cells that may occur 
singly, in pairs forming a V or a Y shape, or arranged in “Chinese characters”. They have 
a peculiar metabolism leading to the formation of propionic acid as main end-product of 
fermentation.  
Although in 1861, Louis Pasteur demonstrated that propionic fermentation was due to the 
biochemical activity of microorganisms, the first studies about the morphology and 
physiology of propionibacteria were carried out by Albert Fitz (1879) [3], who observed that 
organisms from cheeses with “eyes” ferment lactate to propionic and acetic acids and 
liberate carbon dioxide.  
By the beginning of the XXth century, E. Von Freudenreich and Sigurd Orla-Jensen (1906) [4] 
isolated the bacteria responsible for the “eyes” formation in Emmental cheese and some 
years later, the name Propionibacterium was suggested by Orla-Jensen [5] for referring to 
bacteria that produced large amounts of propionic acid. Although several strains were 
isolated during the following years these microorganisms were not included in the Bergey’s 
Manual of Determinative Bacteriology till the third edition published in 1930. Since then, 
new species were described on the basis of their morphological and biochemical 
characteristics such as their typical pattern of Chinese characters, propionic acid production, 
and carbohydrate fermentation profile.  
In 1972, Johnson and Cummins [6], classified strains with several common features into 
eight homology groups based on DNA-DNA hybridization and peptidoglycan 
characteristics. This study was the basis for the classification of propionibacteria into 
“dairy or classical” and “cutaneous” groups included in the 8th edition of Bergey’s 
Manual of Determinative Bacteriology (1974). Four dairy species were recognized in this 
edition: P. freudenreichii and their three subespecies (freudenreichii, shermanii y globosum), 
P. thoenii, P. jensenii and P.acidipropionici whereas other four species that inhabit the 
human skin were ascribed to the cutaneous propionibacteria: P. acnes, P. avidum, P. 
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lymphophylum and P.granulosum. The same scheme was followed in the first edition of 
Bergey’s Manual of Systematic Bacteriology [1]. In 1988, on the basis of 16S rRNA 
sequences, the species Arachnia propionica was reclassified as Propionibacterium propionicus 
[7]. Then, in Bergey’s Manual 9th edition (1994), the classification of previous edition 
was maintained but the subspecies P. freudenreichii subsp. globosum was removed 
without justification. Other species like P. inoccuum and P lymphophilum were then also 
reclassified as Propioniferax innocua [8] and Propionimicrobium lymphophilum [9], 
respectively. 
In the last two decades six new species were isolated: P. cyclohexanicum was obtained from 
spoiled orange juice [10]; P. microaerophilum was isolated from olive mill wastewater [11]; P. 
australiense came from granulomatous bovine lesions [12] and P. acidifaciens from human 
carious dentine [13]. Recently, a new species isolated from human humerus, P. humerusii, 
has been proposed [14].  
At present, the genus Propionibacterium is classified as Actinobacteria with a high G+C 
content, that make them more related to corynebacteria and mycobacteria than lactic acid 
bacteria. The current taxonomic position of propionibacteria is the following [2]: Phylum 
Actinobacteria; Class Actinobacteria; Subclass Actinobacteridae; Order Actinomycetales; 
Suborder Propionibacterineae; Family Propionibacteriaceae; Genus Propionibacterium. 
In the more conventional and general way, propionibacteria are divided based on habitat of 
origin, in two main groups:  
 “Dairy or classical propionibacteria” that inhabit dairy environments and silages, and 
 “Cutaneous propionibacteria” that inhabit the skin and the intestine of humans and 
animals.  
Classical propionibacteria include among their main habitats: raw milk and cheese [1, 2] but 
have been obtained also from silages and vegetables for human consumption [15], and from 
ruminal content and feces of cows and calves [16]. Furthermore, they are not limited to the 
gastrointestinal tract of ruminants being also isolated from the intestine of pigs and laying 
hens [17].  
On the other side, cutaneous species are found mainly in the human skin, but have been 
isolated also from the intestine of humans, chicken and pigs [1, 2, 18], being best represented 
by the acne bacillus, Propionibacterium acnes.  
The 13 species known up to now are listed in Table 1.  
From a safety point of view, classical species have a long history of safe application on 
industrial processes whereas members of the cutaneous group are commonly considered 
opportunistic pathogens in compromised hosts. In consequence, the economic relevance of 
propionibacteria derives mainly from the industrial application of dairy species as cheese 
starters and as biological producers of propionic acid and other metabolites with a more 
recent interest on their usage as health promoters. 
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“Dairy or classical” propionibacteria “Cutaneous” propionibacteria
P. acidicpropionici P. acidifaciens 
P. cyclohexanicum  P. acnes 
P. freudenreichii P. australiense  
P. jensenii P. avidum 
P. microaerophilum P. granulosum  
P. thoenii P. humerusii 
 P. propionicus 
Table 1. Current species of the genus Propionibacterium 
Isolation and enumeration of propionibacteria can be made by microbial culture and 
molecular methods [19]. Various agarized media with different degrees of selectivity have 
been used for detection and enumeration of classical propionibacteria in dairy 
environments, animal and human fecal samples. Among them it could be mentioned YELA 
[20], Pal Propiobac® medium, which contains glycerol, lithium lactate and antibiotics [21] or 
others including lithium chloride and sodium lactate in concentrations high enough to limit 
the growth of accompanying bacteria [22]. In all cases, incubations are made in anaerobiosis 
with an atmosphere of 10–20% CO2. Although these media may be successful for the 
isolation of classical and cutaneous strains of Propionibacterium, they have limitations for 
selective enumeration of bacteria in very complex ecosystems like intestinal microbiota. 
Furthermore, plate count methods for propionibacteria are time consuming since long 
incubation periods for at least 6 days are needed to obtain typical colonies and 
enumerations may be underestimated due to aggregation of bacteria in the diluents used, 
and/or growth inhibition by the selective agents used. 
Molecular methods are a valuable alternative to plating assays, being far more specific, and 
unhindered by the presence of non-target microorganisms. Different fingerprinting methods 
such as SDS-PAGE of whole cell proteins [23], 16s rDNA targeted PCR-RFLP [24], 
ribotyping [25], 16S-23S ribosomal spacer amplification and restriction [26], Pulsed-Field Gel 
Electrophoresis [27], Conventional Gel Electrophoresis Restriction Endonuclease Analysis 
(CGE-REA) and Randomly Amplified Polymorphic DNA-PCR [28] have been used for 
detection and accurate identification of dairy propionibacteria from various environments 
like milk, cheese, whey and flour. Genus and species-specific primers targeted to the genes 
encoding 16S rRNA for PCR-based assays were also designed for detection of dairy 
propionibacteria [29].  
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Recently, a multicolor fluorescent in situ hybridization (FISH) assay targeting the 16S rRNA 
[30] or 23S rRNA [31] of P.acnes was developed and used to detect this bacterium in blood 
samples and tissues of patients with prostate cancer, respectively. A FISH protocol and 
oligonucleotide probes targeting the 16S rRNA of dairy propionibacteria were developed in 
our laboratory [32] and successfully used for enumeration of P. acidipropionici in cecal 
samples of mice fed with a strain of this species [33].  
Finally, a real-time PCR method, based on the transcription of the enzyme transcarboxylase 
involved in propionic fermentation, was successfully used to detect a strain of P. 
freudenreichii in the intestinal ecosystem [34] and would be a valuable tool for monitoring 
survival and metabolic activity of propionibacteria in different environments. 
2.2. Genotypic characteristic of Propionibacterium 
The members of the genus Propionibacterium possess a circular-shaped chromosome like 
most bacteria that varies in size between 2.3 and 3.2 Mb depending on the different species 
[35]. The G+C content in their DNA is in the range of 53-68 mol% and although they 
generally do not possess plasmids their existence has been reported in strains of P. 
acidipropionici, P. freudenreichii and P. jensenii [36]. In fact, it has been informed that between 
10 and 30% of P. freudenreichii strains possess one or two cryptic plasmids [37]. The presence 
of two types of bacteriophages has also been described for propionibacteria. One of them, 
the bacteriophage B22, belongs to the Group B1 of Bradley classification, whereas the other, 
bacteriophage B5, would be the first infectious filamentous virus described in a Gram 
positive bacterium [38].  
Up to few years ago, the only completely sequenced and publicly available genome within 
the genus Propionibacterium was that of the commensal cutaneous species P. acnes [39]. 
However, in the year 2010, the complete genome of a species that belongs to the taxonomic 
group of dairy propionibacteria was described for the first time.  
The genome of the type strain, P. freudenreichii subsp. shermanii strain CIRM-BIAlT, was 
sequenced with an 11-fold coverage [40]. It consists of a circular chromosome of 
2,616,384 base pairs (bp) with 67% GC content, 2 rRNA operons and 45 tRNAs. The 
chromosome is predicted to contain 2439 protein-coding genes and also contains 22 
different insertion sequences that represent 3.47% (in base pairs) of the genome. Insertion 
sequences and transposable elements may promote genome plasticity and induce 
phenotypic changes that contribute to bacterial adaptation to different environments; 
being particular for propionibacteria the synthesis of capsular EPS and the ability to 
ferment lactose [40]. 
P. freudenreichii subsp. shermanii CIRM-BIAlT is able to metabolize lactose, although this trait 
is strain-dependent, since the Lac genes may have been acquired through a horizontal 
transfer event mediated by phage infection. In this sense it should be emphasized that the 
presence of the enzyme β-galactosidase should be the only feature that allows these bacteria 
to adapt to dairy niches like cheeses. 
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The genome sequence also showed that P. freudenreichii possesses a complete enzymatic 
machinery for de novo biosynthesis of aminoacids and vitamins (except panthotenate and 
biotin) and genes involved in the metabolism of carbon sources, immunity against phages, 
chaperones for stress resistance, and storage of inorganic polyphosphate, glycogen and 
compatible solutes such as trehalose that confer these bacteria a long survival in 
stationary phase [40]. Although propionibacteria are usually described as anaerobes, all 
the genes encoding enzymes required for aerobic respiration such as NADH 
dehydrogenase, succinate dehydrogenase, cytochrome bd complex, ATPase and the 
complete pathway for heme synthesis have been identified in the genome of P. 
freudenreichii [40]. 
With respect to technological application in dairy industries, various pathways for 
formation of cheese flavor compounds were identified in the genome of this strain such 
as the enzymes involved in the production of propionic acid, volatile branched chain 
fatty acids from amino acid degradation, and free fatty acids and esters from lipids 
catabolism. 
In relation to probiotic functionality, it has been identified the complete biosynthesis 
pathway for a bifidogenic compound (DHNA) as well as the sequences corresponding to a 
high number of surface proteins involved in the interactions with the host (like adhesion 
and immunomodulation). By comparative genomics with P. acnes, no pathogenicity factors 
were identified in P. freudenreichii, which is consistent with the Generally Recognized As 
Safe and Qualified Presumption of Safety status of this species. 
2.3. Main physiological characteristics of Propionibacterium  
Propionibacteria are heterotrophic microorganisms that mean they need an organic carbon 
source to grow and posses a fermentative metabolism [41-43]. They degrade carbohydrates 
like glucose, galactose, lactose, fructose and other sugars; poliols like glycerol; erythritol and 
others; and organic acids such as lactic and gluconic acids producing propionic, acetic and 
CO2 as the main fermentation end-products [1].  
The production of propionic acid by these bacteria involves a complex metabolic cycle with 
several reactions in which substrates are metabolized to pyruvate via glycolysis, pentose 
phosphate or the Entner-Doudoroff pathways, generating ATP and reduced co-enzymes. 
Pyruvate is then oxidised to acetate and CO2 or reduced to propionate. The latter 
transformation occurs via the Wood-Werkman cycle or transcarboxilase cycle which 
represents the key component of the central carbon metabolic pathway in propionibacteria 
[41].  
The most important reaction of this cycle is transcarboxylation that transfers a carboxyl 
group from methyllmalonyl-CoA to pyruvate to form oxaloacetate and propionyl-CoA, 
without ATP consumption. The enzyme catalyzing this reaction is a methylmalonyl-CoA 
carboxytransferase that has been fully characterized and its structure resolved [34; 40].  
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Then, oxaloacetate is reduced to succinate, via malate and fumarate in two NADH requiring 
reactions. Succinate is then converted to propionate via methylmalonyl-CoA intermediates 
(succinyl-CoA and propionyl-CoA); the carboxyl group removed from methylmalonyl-CoA 
is transferred to pyruvate to yield oxaloacetate, thus completing one cycle. Methylmalonyl-
CoA is also regenerated from succinyl-CoA during propionate production, thus creating the 
second of the two transcarboxylase cycles, and can react with a new molecule of pyruvate. 
All the reactions of this cycle are reversible. It must be emphasized that the Wood Werkman 
cycle used by propionibacteria to produce propionate is coupled to oxidative 
phosphorylation and yields more ATP than in the other bacteria producing propionic acid 
[42, 43]. 
Depending on the strains, the substrate used, and the environmental conditions, 
propionibacteria modulate the proportions of pyruvate either reduced to propionate, or 
oxidised to acetate and CO2, to maintain the redox balance [43]. In this way the oxidation 
of glucose and lactic acid leads to a molar ratio of propionate:acetate of 2:1 whereas the 
oxidation of glycerol leads to the formation of propionate only. The co-metabolism of 
aspartate/asparagine and lactate has also been reported [44]. During lactate fermentation, 
aspartate is deaminated to fumarate by an aspartate ammonia lyase; fumarate is then 
converted to succinate, with a concomitant production of NAD and ATP. Cells using this 
pathway convert less pyruvate to propionate and oxidised more pyruvate to 
acetate+CO2. 
 
Figure 1. Propionic acid fermentation in propionibacteria 
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Propionibacteria are also mesophilic microorganisms, with optimal growth conditions at 30 
ºC and pH 6.8. However, they grow in a temperature range between 15 a 40 ºC and tolerate 
pH variations between 5.1 and 8.5 [1, 2]. Their nutritional requirements are low and almost 
the same for all the species. Dairy propionibacteria like P. freudenreichii are able to synthesize 
all amino acids [40]. They can grow in a minimal medium containing ammonium as the sole 
nitrogen source, but a higher growth is observed in media containing amino acids [45]. 
Although P. freudenreichii subspecies shermanii is able to ferment lactose, dairy 
propionibacteria show poor growth in milk, as they do not possess proteases capable of 
hydrolyzing milk caseins [46]. Some proteinases have been described for Propionibacterium, 
one cell wall associated and one intracellular or membrane bound but their activities are 
weak. By contrast, different peptidases such as aminopeptidases, proline iminopeptidase, 
proline imidopeptidase, X-prolyl-dipeptidyl-amino-peptidase, endopeptidases and 
carboxypeptidase, have been described. and characterized. Amino acids, especially aspartic 
acid, alanine, serine and glycine, are degraded by Propionibacterium, with variations among 
species and strain [47]. On the other side, cutaneous propionibacteria, have the ability to 
hydrolyze different proteins, like gelatin and fibronectin, and to promote damages and 
inflammation of the host tissues. 
Regarding vitamins, all propionibacteria strains require pantothenate (vitamin B5) and biotin 
(vitamin H). In addition, some strains require thiamine (B1) and p-aminobenzoic acid [40, 41].  
2.4. Long term and stress survival of Propionibacteria  
It is known that propionibacteria are able to adapt and survive to different stresses like 
industrial processes and the gastrointestinal transit, as well as to remain active for long 
periods of time in such adverse environments [43].  
In this sense, the manufacture of a swiss type cheese represents for microbial starters 
successive stresses like acidification of the curd, heating during cooking, osmotic stress due 
to brining, and low temperature (4 to 12 °C) during cheese ripening. The transit through the 
digestive tract also suppose stressful conditions for bacteria such as gastric acidity and the 
presence of other aggressive intestinal fluids like bile and pancreatic enzymes.  
Interestingly, the cell machinery involved in general stress adaptation in P. freudenreichii was 
shown to be encoded by multicopy stress-induced genes [40]. The redundancy and 
inducibility of this chaperone and protease machinery is in agreement with the ability of P. 
freudenreichii to adapt rapidly and efficiently to various unfavorable conditions [48-50]. 
The stress adaptation proteins were particularly investigated in P. freudenreichii and its 
genome, finding out that they are differentially expressed depending on the strain and 
the stress [40, 48-50]. Acid and bile stresses, induce the synthesis of the following 
proteins: pyruvate-flavodoxin oxidoreductase and succinate dehydrogenase which are 
involved in electron transport and ATP synthesis, as well as glutamate decarboxylase 
and aspartate ammonia-lyase, which are involved in intracellular pH homeostasis. Bile 
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also induces oxidative stress so that survival and activity within the gut depend on 
remediation of oxidative damages. P. freudenreichii possesses an arsenal of genes for 
disulfide-reduction and elimination of reactive oxygen species. Moreover, in response to 
bile salts, P. freudenreichii overexpresses the iron/manganese superoxide dismutase, 
Glutathione-S-transferase, two cysteine synthases and S-adenosylmethionine synthetase 
[40]. The occurrence of a sodium/bile acid symporter (PFREUD_14830) reflects 
adaptation to the gut environment. Other inducible proteins involved in protection and 
repair of DNA damages include Ssb protein which is involved in DNA recombination 
and repair, as well as Dps which protects DNA against oxidative stress are stress-
induced in P. freudenreichii [49]. 
With respect to thermotolerance, the over-expression of constitutive stress-related 
molecular chaperones and ATP-dependent proteases as well as the induction of the 
dihydroxyacetone kinase locus (dhaKL, PFREUD_07980 and PFREUD_07990) by stress 
and starvation seems to be related to survival to thermal stress by difference to 
thermosensitive strains [40, 50].  
Stress tolerance and cross-protection in strains of Propionibacterium freudenreichii were 
examined after exposure to heat, acid, bile and osmotic stresses. Cross-protection 
between bile salts and heat adaptation was demonstrated. By contrast, some other 
heterologous pretreatments (hypothermic and hyperosmotic) had no effect on tolerance 
to bile salts. Furthermore, acid pretreatment sensitized cells to bile salts challenge and 
vice versa. Heat and acid responses did not present significant cross-protection and no 
cross-protection of salt-adapted cells against heat stress was observed for these 
propionibacteria [48-50]. 
In addition, long term survival of propionibacteria on adverse environments could be due to 
the accumulation of storage compounds, compatible solutes, and the induction of a multi-
tolerance response under carbon starvation [40]. In contrast to other bacteria that use ATP, 
P. freudenreichii accumulates inorganic polyphosphate (polyP) as energy reserve. Short 
chains of PolyP are synthesized when bacteria grow on glucose whereas long chains are 
accumulated when the main carbon source is lactate. The synthesis of PolyP is catalysed by 
polyphosphate kinase (PPK) that transfers the terminal phosphate of ATP to polyP. It is 
proposed that PolyPs enable microorganisms to tolerate adverse conditions since ppk 
mutants are unable to survive during stationary phase [51]. The genes encoding for polyP or 
pyrophosphate (instead of ATP) using enzymes were found in the genome of P.freudenreichii 
CIRM-BIA1T [40]. 
Propionibacteria is also able to synthesize glycogen and all the genes related to glycogen 
metabolism were identified in the genome of the strain P.freudenreichii CIRM-BIA1T [40]. 
Some of these genes were also found in P. acnes. These enzymes seem to be involved in 
intracellular accumulation and hydrolysis of glycogen as neither P. freudenreichii nor P. acnes 
are able to ferment extracellular glycogen 
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It has been reported that propionibacteria are able to withstand osmotic stress by 
accumulation of compatible solutes like glycine betaine and trehalose [52]. Trehalose is a 
non-reducing disaccharide that can be used by bacteria as a carbon and energy source and 
also can be accumulated as a compatible solute. All dairy propionibacteria are able, in a 
strain dependent manner, to synthesize and accumulate trehalose from glucose and 
pyruvate [53]. Both processes are enhanced at stationary phase and under oxidative, 
osmotic, and acid stress conditions [54]. Trehalose is commonly synthesised via the 
trehalose-6-phosphate synthase/phosphatase (OtsA–OtsB) pathway and catabolised by 
trehalose synthase (TreS). The genes otsA, otsB, and treS were identified in P. freudenreichii 
by Cardoso et al., 2007 [55] and Falentin et al 2010 [40]. 
It is also known that dairy propionibacteria survive for many months at room 
temperature even under conditions of carbon starvation, being the majority of the strains 
non-lytic [2]. This long-term survival in stationary phase or dormant phase could be the 
consequence of a multi-tolerance response that involves the synthesis and accumulation 
of polyP, glycogen, trehalose and the over-expression of molecular protein chaperones. 
Besides, a gene encoding an Rpf (resuscitation promoting factor) protein which is 
essential for the growth of dormant cells from actinobacteria has been described in the 
genome of P freudenreichii and is probably involved in long-term survival of 
propionibacteria [40].  
3. Technological importance of dairy propionibacteria 
3.1. Dairy starters for Swiss-type cheeses and other products 
The main industrial application of the genus Propionibacterium is the usage of “classical 
propionibacteria” as dairy starters for the manufacture or Swiss type cheeses. This 
denomination refers to cheese varieties, such as Sbrinz, Emmental, Gruyère, Compté, 
Appenzeller and others riddled with holes and made with raw or pasteurized milk 
(depending on the variety). 
In these products propionibacteria are responsible for the typical sweet, nutty taste by 
production of acetic and propionic acids; aminoacids like proline and leucine but mainly for 
the characteristic “eyes” formation by releasing of CO2 [56-57]. However, propionibacteria 
can also be used in the manufacture of various cheeses without eyes just to enhance flavour 
formation [58]. 
In swiss type cheeses, propionibacteria may be present either as contaminants of raw milk 
or as components of starter cultures. The typical starter for this variety includes 
Streptococcus thermophilus, Lactobacillus helveticus, Lactobacillus delbrueckii subsps. lactis or 
bulgaricus and Propionibacterium freudenreichii. During manufacture and early stages of 
ripening, the thermophilic bacteria develop at expense of lactose of milk being responsible 
for lactic acid production, and also contributing to casein hydrolysis during pressing of 
the cheese.  
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Interactions between microbiota and milk throughout ripening lead to biochemical 
changes that result in the development of the typical texture and flavor. During 
maturation in the cold room (15 °C) most of lactic starter lyse and release peptidases that 
produce free amino acids, which are precursors of many flavor compounds. The 
subsequent period of warm room ripening is characterized by a marked growth of 
propionibacteria that metabolize the lactate produced by the lactic acid bacteria into 
propionate, acetate and CO2. At the end of maturation that ranges from 6 weeks to 12 - 18 
months in the hardest varieties, the number of propionibacteria reaches 108 - 109 cfu/g of 
cheese [41, 57].  
P. freudenreichii greatly contributes to Swiss-type cheese flavour by producing compounds 
from three main pathways: lactate and aspartate fermentation, amino acid catabolism, 
and fat hydrolysis [59]. As described above, the end-products of propionic fermentation 
are considered as flavour compounds in cheese whereas the co-metabolism of aspartate 
leads to additional CO2 production. However, strains with a high ability to metabolise 
aspartate can be associated with undesirable slits and cracks [60]. 
Propionibacteria degrade branched-chain amino acids to branched-chain volatile 
compounds mainly 2-methylbutanoic acid and 3-methylbutanoic acid, which derive from 
isoleucine and leucine degradation, respectively [61]. These important flavour compounds 
are almost entirely produced in cheese by propionibacteria that synthesize them in closely 
related manner to that of cell membrane fatty acids [62].  
P. freudenreichii also contributes in a great manner to cheese lipolysis by releasing free 
fatty acids from fat during cheese ripening. Two esterases, one extracellular and other 
surface-exposed seem to be involved in lipolysis of milk glycerides [63, 64]. Furthermore, 
ten intracellular esterases were found in the P. freudenreichii genome that could be 
involved in the synthesis of the volatile esters associated with the fruity flavor of cheese 
[65]. 
In contrast, although it possesses diverse intracellular peptidases, P. freudenreichii has a 
limited role in secondary proteolysis, compared to starter and non-starter lactic acid bacteria 
(NSLAB), because it does not lyse in cheese [66]. 
It is important to emphasize that propionibacteria maintain metabolic activity up to the end 
of ripening, as shown by molecular methods [68] producing flavour compounds during 
growth in cheeses at 24 °C, and further cold storage [60].  
Other dairy products such as yogurt and fermented milks seem to be less appropriated for 
delivery of propionibacteria due to their weak proteolitic activity, the presence of inhibitory 
substances and the low pH attained by lactic acid fermentation that do not allow their 
development. Currently, yogurt is used to deliver probiotic propionibacteria to the host’s 
intestine or to produce nutraceuticals, but in both cases inoculums higher than those used 
for cheese manufacturing are necessary.  
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3.2. Antimicrobials production: Propionic acid and bacteriocins 
Propionic acid and its salts, as well as Propionibacterium spp strains, are widely used as food 
and grain preservatives due to their antimicrobial activity at low pH. They are commonly 
incorporated in the food industry to prolong the shelf-life of many products by suppressing 
the growth of mold and spoilage microorganisms in bread and cakes, on the surface of 
cheeses, meats, fruits, vegetables, and tobacco.  
Most commercial propionic acid is produced by petrochemical processes since biosynthesis 
by microbial fermentation is limited by low productivity, low conversion efficiency, by-
product formation (acetic acid and succinic acid) and end-product inhibition. However, 
different attempts have been made to improve biological production of propionic acid for 
industrial applications [68]. In this sense, it has been determined that the most appropriated 
species for bioproduction of propionic acid from carbohydrate-based feedstock, including 
glucose and whey lactose, is P.acidipropionici [69, 70]. Since the use of glycerol as the 
principal carbon source enables the production of propionic acid without acetic acid, recent 
investigations have focused on the optimization of this particular homopropionic 
fermentation by propionibacteria [71, 72].  
Two commercial products that include propionibacteria or their metabolites aimed for 
controlling spoilage microorganisms are currently available at market. Microgard™ is a 
food grade biopreservative obtained by fermentation of skim milk with Propionibacterium 
shermanii that is active against some fungi and Gram negative bacteria, but not against Gram 
positive ones [73]. The other product named BioProfit, contains viable cells of P. 
freudenreichii subsp shermanii strain JS and is effective for inhibiting yeasts growth in dairy 
products, Bacillus spp. in sourdough bread [74]; and also used to preserve grain and 
produce good quality silages [75]. 
Propionic acid, produced in vivo in the gut by viable bacteria, is also a desired healthy 
metabolite, as it is related to many probiotic properties of propionibacteria (as will be 
described below). In this respect, it has been demonstrated that SCFA favours the colonic 
recovery of water and electrolytes counteracting the osmotic diarrhea induced by lactose 
and/or other unabsorbed carbohydrates [76]. Besides, they exert anticarcinogenic effects by 
inducing apoptosis of neoplastic cells but not of healthy mucosa [77]. Finally, SCFA may 
exert hypocholesterolemic effects, since propionate lowers blood glucose and alters lipid 
metabolism by suppressing cholesterol synthesis in the liver and intestine [78]. 
Bacteriocins are antimicrobial peptides or proteins encoded by plasmid or chromosomal 
DNA of a wide range of Gram positive and negative bacteria. They have an antagonistic 
activity against species genetically related to the producer strain, but many of them exhibit a 
rather wide spectrum of activity and inhibit the growth of spoilage and pathogenic bacteria 
belonging to other genera [79]. 
Both starters and naturally occurring bacteria on food have the ability to produce 
bacteriocins. Hence, they may have potentially important applications as food 
biopreservatives or bacteriocin-producer probiotics to inhibit intestinal pathogens [80]. 
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However, only nisin, a bacteriocin produced by Lactococcus lactis subsp. lactis, has attained 
the GRAS status of the FDA for use in certain foods. 
Different bacteriocins produced by both dairy and cutaneous propionibacteria have been 
reported and characterized. Among them it could be mentioned: Propionicin PLG-1 and 
GBZ-1 produced by P. thoenii 127 [81]; Jenseniin G isolated from P. thoenii P126 [82]; 
Propionicins SM1 and SM2 produced by P. jensenii DF1 [83]; Propionicin T1 synthesized by 
P. thoenii 419 and LMG2792 [84]; Thoenicin 447 isolated from P. thoenii 447 [85]; Acnecin 
produced by a strain of P. acnes [86] and several other propionicins [87-89]. 
These bacteriocins are active against other propionibacteria, lactic acid bacteria (Lactobacillus, 
Lactococcus and Streptococcus), other Gram positive bacteria (Clostridium botulinum types A, B 
and E), Gram negative bacteria (Campylobacter jejuni, E. coli, Ps. fluorescens, Ps. aeruginosa, 
Vibrio parahaemolyticus Salmonella typhimurium, Yersinia enterocolitica); yeasts (Saccharomyces, 
Candida y Scopularopsis sp) and molds (Aspergillus ventii, Apiotrichum curvatum, Fusarium 
tricinctum, Phialophora gregata). 
Although the ability of dairy propionibacteria to produce bacteriocins in situ in food 
products or inside the intestine has not been demonstrated yet, they have a potential 
application as safe biopreservatives. In this respect, some efforts have been made to improve 
the production processes [90] since the slow growth, late bacteriocin synthesis and low 
production represent limitations for the practical application of bacteriocin-producer 
propionibacteria. 
Propionibacteria also produce other peptides and organic acids (2-pyrrolidone-5-carboxylic 
acid, 3-phenyllactic acid, hydroxyphenyl lactic acid 3-phenyllactic acid) with antiviral, 
antiyeasts and antifungal activities [91-93]. 
3.3. Nutraceuticals production: CLA, vitamins, EPS and trehalose 
Propionibacteria are able to produce many biological compounds that enhance the human 
health so they can be used as “nutraceuticals cell factories” for food enrichment. In this 
regard, propionibacteria have already been considered as rich sources of conjugated linoleic 
acid, vitamins, exopolysaccharides and trehalose. 
Many health benefits have been attributed to consumption of CLA-containing foods such as 
anticarcinogenic, antiatherogenic, antidiabetogenic and antioxidative properties, immune 
system modulation and reduction of body fat gain [94]. CLA-isomers are formed by 
biohydrogenation of LA in the rumen and through conversion of vaccenic acid by Δ9-
destaurase in the mammary gland so that ruminant meats and milk-derived products are 
main dietary sources of CLA. However, some microorganisms like Bifidobacterium, 
Lactobacillus, Enterococcus and Propionibacterium posses a linoleic acid isomerase that allow 
them to form CLA as a detoxification mechanism [95]. In consequence, they have been 
intended, either as starter or adjunct cultures, to increase the CLA level and nutritional 
value of some fermented products like yoghurt and cheese.  
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In this regard, several studies have shown the potential of propionibacteria for 
producing CLA enriched products. Both growing and resting cells of dairy (P. 
freudenreichii) [96, 97] and cutaneous propionibacteria (P. acnes) [98] produce cis-9, trans-
11 and trans-10, cis-12, the major isomers with biological activity, on different growth 
media: culture broths [97], lipid containing plant materials [99], milk and ripening cheese 
[100].  
By varying the source of LA for conjugation and the fermentation conditions it has been 
observed that P. freudenreichii convert free LA to mainly extracellular CLA with a high 
efficiency (50-90%), being the optimal conditions that favor the accumulation of CLA also 
determined [97, 101]. Besides, it has been observed that CLA formation and growth of dairy 
propionibacteria in fermented milks were enhanced in the presence of yogurt 
microorganisms whereas organoleptic attributes obtained with yogurt starter cultures were 
not affected by co-cultures with the propionibacteria [100].  
Vitamin B12 also called cobalamin, is an essential nutrient for the human body that plays a 
key role in the normal functioning of the brain and nervous system, the formation of blood 
and also the metabolism of every cell, especially affecting DNA synthesis and regulation, 
fatty acid synthesis and energy production. Its deficiency leads to a serious physiological 
disorder called pernicious anemia.  
The pathway of vitamin B12 synthesis in Propionibacterium freudenreichii has been completely 
elucidated [40, 102]. This microorganism synthesizes cobalamin as a cofactor for propionic 
acid fermentation [41] and is the only bacteria, among B12 producers that possess the GRAS 
status of the United States Food and Drug Administration. 
In consequence dairy propionibacteria are the preferred microorganisms for the industrial 
production of this vitamin and many efforts have been made to improve the production 
process by using genetic engineering [102, 103] and other biotechnological strategies like 
fermentation manipulations [104, 105].  
Vitamin B2, also known as riboflavin, is the central component of the cofactors FAD and 
FMN, and is therefore required by all flavoproteins. As such, vitamin B2 is required for a 
wide variety of cellular reactions and is involved in vital metabolic processes in the body. It 
has been reported that P. freudenreichii NIZO2336, a mutant strain that produces larger 
amounts of riboflavin than the parental strain, improved riboflavin content of yogurt and 
riboflavin status of rats fed with this product [106]. 
Different studies have shown the possibility to obtain genetically modified strains of P. 
freudenreichii that overproduce B12 vitamin [102, 107], porphyrin [108], and riboflavin 
(vitamin B2) [107]. 
Propionibacteria also produce Vitamin B7 (biotin) and Vitamin B9 (folic acid), so that 
propionibacteria-containing products could be expected to be good sources of B-group 
vitamins.  
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Vitamin K (a group of 2-methyl-1,4-naphthoquinone derivatives), is an essential cofactor for 
the formation of γ-carboxyglutamic acid-containing proteins that bind calcium ions and are 
involved in blood coagulation and tissue calcification. Its deficiency has been associated 
with low bone density and increased risk of fractures from osteoporosis and intracranial 
hemorrhage in newborns [109]. Vitamin K1 or phylloquinone is present in plants, and 
vitamin K2, also called menaquinone, is produced in animals and bacteria that live in the 
intestine.  
It has been reported that Propionibacterium freudenreichii produces large amounts of 
tetrahydromenaquinone-9 (MK-9 (4H)) and the precursor 1,4-dyhidroxy-2-naphtoicacid 
(DHNA) which is a known bifidogenic factor [110-112]. In order to improve the production 
of these metabolites, different laboratory culture protocols that could be applied to an 
industrial scale have been assayed finding out that DHNA production is markedly 
influenced by carbon source limitation and the oxygen supply. An improvement in DHNA 
production could be obtained by a cultivation method that combines anaerobic fed-batch 
and aerobic batch cultures [112, 113].  
In another study, Hojo et al. [114] assessed the concentration of MK-9 (4H) in commercial 
propionibacteria-fermented cheeses finding out a positive correlation between the increase 
in propionibacteria and the generation of MK-9 (4H) in cheese. Due to their high MK-9 (4H) 
concentrations (200 to 650 ng/g), Emmental and Jarlsberg cheeses should be a meaningful 
source of vitamin K and potential protectors against osteoporosis. 
Exopolysaccharides-producing bacteria and their secreted EPS are important biological 
thickeners for food industry. Besides, some health promoting properties such  
as immunomodulation and cholesterol lowering activities have been ascribed to EPS 
[115]. 
In dairy propionibacteria (P.freudenreichii subsp. shermanii), the single gene gtf encoding for a 
β-d-glucan synthase that is responsible for the synthesis of surface polysaccharide has been 
identified [40, 116] and the EPS produced was also characterized. Both homopolysaccharide 
[116, 117] and heteropolymers [118] were described and it has been reported that production 
of EPS by propionibacteria is a strain-dependent property (due to an IS element in the gtf 
promoting sequence) that is influenced by the medium composition and the fermentation 
conditions [119, 120]. Further studies are needed to elucidate the role of these polymers and 
their potential applications. 
Trehalose has been proposed as a healthy sugar substitute in foods because of its 
anticariogenic and dietetic properties. As described in paragraphs above, propionibacteria 
synthesize trehalose as a reserve compound and as a stress-response metabolite [52-55]. 
With respect to the production of this sugar in situ in food products, it has been observed 
that P. freudenreichii ssp. shermanii NIZO B365 produces high levels of trehalose in skim 
milk [54]. 
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Technological 
property 
General comments References 
Dairy starter Propionibacterium freudenreichii is included in 
the starter of Swiss type cheeses. It 
contributes to the typical flavor and the 
development of characteristic “eyes” 
[56, 57], [59]. 
Antimicrobials P. acidipropionici could be considered for 
biological production or propionic acid to 
be used as food preservative. 
Microgard™ and BioProfit are commercial 
products that include propionibacteria 
aimed for controlling spoilage 
microorganisms. 
 
Different bacteriocins are produced by both 
dairy and cutaneous propionibacteria that 
are active against gram positive and gram 
negative bacteria. They have a potential 










CLA  Propionibacteria produce cis-9, trans-11 and 
trans-10, cis-12, CLA isomers on culture 
broths; lipid containing plant materials; 
milk and ripening cheese. They have 




Vitamins Propionibacterium freudenreichii is the only 
GRAS status producer of Group B vitamins: 
B2, B7 (biotin), B9 (folic acid) and B12. 
Genetically modified overproducer strains 
have been experimentally obtained. 
Propionibacteria produces vitamin K (MK-9 







EPS Propionibacteria produce homo and 
heteropolysaccharides that could be used as 
food thickeners. 
[117, 121]. 
Trehalose P. freudenreichii synthesizes trehalose that 
coud be used as sugar substitute in foods 
[54]. 
Table 2. Technological relevance of the genus Propionibacterium 
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4. Probiotic application of dairy propionibacteria 
Since the last decades, there has been an increasing interest from food and 
pharmaceutical industries to develop healthy foods and therapeutic alternatives to 
conventional antibiotic treatments in response to consumers’ demands of natural 
products. Probiotics are “live microorganisms that confer health benefits to the host 
when administered in adequate amounts” [121]. In this respect, the great bulk of 
evidence concerning the beneficial effects of microorganisms both in human and animal 
health refers to lactic acid bacteria and bifidobacteria as they are common inhabitants of 
the gastrointestinal tract. However, in recent years several potential probiotic properties 
of propionibacteria have been reported and many studies on this subject have been 
published. In the following sections, safety aspects and the major health benefits ascribed 
to dairy propionibacteria are reviewed. 
4.1. Safety and persistence in the gut 
Strains selected on the basis of their potential beneficial effects by in vitro tests, must 
demonstrate their safety both in humans and animals, before they could be incorporated as 
probiotics, either in food or pharmaceutical products. 
In this sense, dairy propionibacteria have a long history of safe use in human diet and 
animal feed. P. freudenreichii is widespread consumed in Swiss type cheeses in which they 
are present in concentrations close to 109 bacteria/g. Besides, classical propionibacteria have 
been isolated from soil, silage, vegetables, raw milk, secondary flora of cheese and other 
naturally fermented food. Therefore, it could be considered that they would arrive to the gut 
of different organisms, including the man, at least once in their lives. 
At present, no cases of sickness or toxicity after the ingestion of dairy propionibacteria have 
been reported [122] neither for humans (for a review of human trials see [123]) nor for 
animals [124-126]. In fact, it has been reported that propionibacteria did not translocate to 
blood, liver or spleen and no adverse effects on body weight gain and general health status 
was observed after short [124, 127] and long terms [125] administration of strains of 
Propionibacterium acidipropionici, P.  freudenreichii and P. jensenii, respectively. 
Most studies have been performed with strains of P. freudenreichii since it is the traditional 
component of cheese starters being this species granted the Generally Recognized As Safe 
(GRAS) status from the US Food and Drug Administration. Furthermore, P. freudenreichii 
belongs with P. acidipropionici, to the list of agents recommended for Qualified Presumption 
of Safety (QPS) by the European Food Safety Authority [122, 128].  
On the other side, most strains isolated from humans and animals belong to the “cutaneous 
group” [18, 129] and their use as probiotics is discouraged since they are potential 
pathogens. However, propionibacteria isolated from the intestine of animals and identified 
by molecular tools as dairy species, were not associated to pathogenesis. 
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Besides safety, other criteria to take into account in the selection of strains for dietary 
adjuncts are the absence of antibiotic resistances (due to the risk of spreading any 
resistance to intestinal microbiota) and virulence factors. Dairy propionibacteria have 
natural resistance to some antibiotics and this resistance does not appear to be encoded 
by plasmids or other mobile genetic elements [36, 122, 130]. By comparative genomics, 
no virulence factors found in P. acnes or in other pathogenic species were identified in P. 
freudenreichii, although some P. thoenii and P. jensenii strains have β-haemolytic activity 
[40, 122].  
In order to exert their beneficial effects in the host, it is generally accepted that ingested 
microorganisms must survive the hostile environmental conditions of the gastrointestinal 
tract represented by the low pH of the stomach and intestinal fluids such as bile and 
pancreatic enzymes. Many studies have demonstrated by in vitro assays the ability of dairy 
propionibacteria to survive and tolerate the gastrointestinal conditions [130-134]. This 
tolerance could be improved by a pre-adaptation of the microorganisms to the adverse 
conditions of the gut by a brief exposure to the stressful conditions at a non-lethal level [48, 
135].  
Both acid and bile tolerance have shown to be strain-dependent properties. In previous 
studies [131, 132] we observed that dairy propionibacteira developed in a medium 
containing bile (0 – 0.5%) behaved as “bile-tolerant” and “non bile-tolerant” strains and that 
there were differences among P. freudenreichii and P. acidipropionici strains in their tolerance 
to pancreatic enzymes when subjected to sequential digestion with artificial gastric and 
intestinal fluids. 
It has also been demonstrated that the vehicle used for delivery of probiotics is important 
for digestive stress tolerance since cells included in food matrices like milk or cheese had 
better tolerance to acid challenge than free cultures [132]. Similar results were obtained by 
Huang and Adams [134], by protecting propionibacteria from acid and bile stresses with a 
soymilk and cereal beverage, and Leverrier et al. [136], who used yoghurt-type fermented 
milk.  
Survival of propionibacteria during gastrointestinal transit has also been reported in vivo in 
rats [125, 126]; mice [124, 137] and humans [127, 130, 133]. Furthermore, Herve et al. [34], 
demonstrated that propionibacteria remain metabolically active since the P. freudenreichii-
specific transcarboxylase mRNA was detected in human faeces. In most studies, a high level 
of propionibacteria was detected in intestinal contents and feces during the feeding period 
but this concentration gradually declined and returned to the initial levels a few weeks after 
consumption ceased. 
Besides surviving the gastrointestinal digestion, intended probiotics must remain in high 
levels in the intestine avoiding normal washout by peristaltic contractions of the gut. 
Therefore, microorganisms with a short generation time and/or the ability to adhere to the 
mucosa would have an extended survival in the body of the host. Bacterial adhesion to 
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intestinal cells and mucus is generally considered as the initial step in the colonization of the 
gut and has been related to many of the health effects of probiotics, as it prolongs the time 
that beneficial bacteria can influence the gastrointestinal microbiota and immune system 
[138]. Since propionibacteria grow slowly in natural environments and culture media, 
adhesion ability becomes an important property in the selection of strains for probiotic 
purposes.  
Dairy propionibacteria have demonstrated to adhere to immobilized mucus [139]; to 
isolated mouse intestinal epithelial cells [140,141], to human intestinal cell lines [142-144] 
and in vivo to intestinal cells as was assessed by counting the adhering propionibacteria on 
the mucosa by a plate count method [124, 125, 137, 145]. 
In previous studies, we have correlated the in vitro and in vivo abilities of dairy 
Propionibacterium strains to adhere to intestinal epithelial cells and observed by scanning 
electron microscopy, that P.acidipropionici CRL 1198 adheres well to IEC or the mucus 
layer covering them [141]. Microscopic examination revealed two adhesion patterns in 
propionibacteria: autoaggregating strains adhere in clusters, with adhesion being 
mediated by only a few bacteria, whereas nonautoaggregating propionibacteria adhere 
individually making contact with each epithelial cell with the entire bacterial surface 
[140].  
Besides, the adhesion of propionibacrteria of different dairy species such as P. freudenreichii 
subsp. shermanii JS, P. jensenii 702 and P. acidipropionici Q4 to Caco-2, C2BBe1 and HT29 cells 
respectively, was clearly stated [142-144]. 
Interactions with the host gut mucosa are also suggested by the analysis of the genome of P. 
freudenreichii that revealed the presence of genes encoding for a high number of surface 
proteins involved in adhesion and present in other probiotic bacteria [40]. 
To date, the ability of dairy propionibacteria (used alone or combined with other 
microorganisms) to improve the health of humans and animals by being used as dietary 
microbial adjuncts has been extensively investigated. Their health promoting effects could 
be attributed to one or more of the following modes of action: i) immunomodulation; ii) 
influence on gut microbial composition and exclusion of pathogens; and iii) modulation of 
the metabolic activities of the microbiota and host. Main evidences obtained by in vitro and 
in vivo studies supporting the potential of dairy propionibacteria to be used as probiotics are 
summarized below. 
4.2. Propionibacteria for improving animal health 
Nowadays, the usage of probiotics as an alternative to antibiotics to enhance the growth and 
health of domestic animals is a growing practice. With this aim, different bacterial genera 
have been isolated from the intestine of farm animals and pets and employed as probiotics, 
such as Lactobacillus, Bifidobacterium and Enterococcus [146].  
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To date, most animal studies have been performed with ruminants (cows, calves, steers), 
chicken, pigs, and to a lesser extent with horses and pets. In this sense, it has been reported 
that dairy propionibacteria administered alone or combined with other microorganisms 
increase the weight gain, feed efficiency and health of different animals such as laying hens 
and broilers [147], pigs [148] and calves [149, 150]. 
Propionibacteria are natural inhabitants of the rumen microbiota. In consequence, they have 
been used as direct-fed microbial (DFM) feed additives in ruminant nutrition with strain-
dependant results on animal performances.  
One desired effect for ruminant probiotics is an improvement in propionate production as it 
is considered the major precursor for hepatic gluconeogenesis that provides substrate for 
lactose synthesis in lactating dairy cows. Various strains of Propionibacterium have increased 
the molar proportion of ruminal propionate when fed to ruminants [151, 152]. In this 
respect, many researches have been done with the dairy strain Propionibacterium 
acidipropionici P169. It has been reported that, when administered to beef cattle, this 
microorganism was able to increase hepatic glucose production via enhanced ruminal 
propionate production and absorption, whereas directly fed to early lactating dairy cows, it 
tended to improve milk proteins content and energetic efficiency during early lactation, 
without affecting the reproductive function [152-154]. In general, these authors concluded 
that strain P169 might have potential as an effective direct-fed microorganism to increase 
milk production in dairy cows. 
In other studies, the supplementation of lactating dairy cows with a DFM product 
containing a mixture of L. acidophilus and P. freudenreichii improved milk and protein yield, 
and apparent digestibility of crude protein, neutral detergent fiber, and acid detergent fiber, 
so that it could be used to enhance the performance of cows subject to heat stress during hot 
weather [155]. 
With respect to calves, a preparation called Proma, which is a blended culture of lactic acid 
bacteria plus P. freudenreichii and a DFM product containing P. jensenii 702 showed to be 
effective to improve weight gain during pre-weaning and weaning periods [149, 150]. 
Propionibacteria have also been assayed as health and growth promoters in monogastric 
animals like pigs, with positive results. Mantere-Alhonen [148] was the first to achieve 
growth promotion in piglets fed with different species of propionibacteria being P 
freudenreichii ssp shermanii the most effective probiotic among the species tested. When 
propionibacteria were fed to piglets in a daily concentration of 2 x 109 cfu/g, the weight gain 
was 9.2-14.5% higher, the fodder demand was 7.2-46.1% lower than the control group and 
the animals had less diarrhoea. In bigger swine, the effects were even more evident. 
Cutaenous propionibacteria have also been used to improve the health of swine. 
Propionibacterium avidum KP-40 showed to be a potent immunomodulator that stimulated 
granulopoiesis as well as a faster body weight gain in pregnant swine and their offspring 
[156]. The usefulness of the prophylactic application of this strain, against porcine microbial 
infections was tested in swine finding out that propionibacteria application caused positive 
 
Probiotic in Animals 174 
immunoregulation of porcine innate immune system effectors, non-specific activation of 
lymphocytes and antibody production that resulted in milder clinical symptoms, faster 
recovery and a larger body weight gain [157, 158]. 
In chicken, both undefined and defined “Nurmi Cultures” have been used to establish an 
intestinal flora that will prevent colonization by pathogenic bacteria in young animals. 
These formulas have shown to be effective for the protection against species of Salmonella 
and other avian pathogens; for immune system stimulation in newborn chicks, and also had 
growth promoting effects [159, 160]. The most frequently assayed bacteria as avian 
probiotics were several species of lactic acid bacteria [146, 159, 160]. Propionibacteria have 
not been widely studied in this ecological niche. However, some authors demonstrated the 
presence of this bacterial group in the ileum and cecum of chickens [161], and cecal Nurmi 
cultures characterized by microbiological and PCR-DGGE techniques, evidenced the 
presence of Propionibacterium propionicus [147]. 
In recent studies, the occurrence of Propionibacterium in different segments of the 
gastrointestinal tract of laying hens was demonstrated. Bacteria from this genus were 
evidenced in 27% of the animals sampled. Half of these isolates were identified by genus 
and species specific PCR as P. acidipropionici, belonging the others to the propionibacteria 
cutaneus group. This report represents the first evidence of dairy propionibacteria as 
inhabitants of the gastrointestinal tract of chickens. Some preliminary studies on the 
probiotic properties of these strains, suggest their potential application as probiotic to 
prevent intestinal infections in poultry [17]. 
4.3. Probiotic properties for human application 
Inmunomodulation: One of the most promoted properties of probiotics is their ability to 
regulate in a positive manner the innate and adaptive responses of the human immune 
system. It is well-documented that cutaneous propionibacteria are potent 
immunomodulators, since they have been tested in several assays both in humans and 
rodents used as animal models [162]. Administration of cutaneous propionibacteria (P. 
avidum, P. granulosum, P. acnes) have shown to be beneficial in the treatment of neoplastic 
and infectious diseases [163-165]. Besides, dead Propionibacterium acnes or a polysaccharide 
extracted from its cell wall have proven to be effective in the induction of macrophages with 
an antitumor effect [166] and in modulating an experimental immunization against 
Trypanosoma cruzi [167].  
With respect to the immunomodulatory properties of dairy propionibacteria, many 
researches have been done in vitro and in vivo with the strain P. freudenreichii subsp. shermanii 
JS. It has been reported that this microorganism stimulated the proliferative activity of B and 
T lymphocytes depending on doses administration and treatment duration in mice [168]. 
Regarding to cytokine production, P. freudenreichii JS was able to induce TNF-α and IL-10 
production in human PBMCs [169] and inhibited the H. pylori-induced IL-8 and PGE2 
release in human intestinal epithelial cells [170].  
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Other dairy P. freudenreichii strains also showed promising immunomodulatory properties 
by strongly inducing the synthesis of anti-inflammatory IL-10 by human PBMCs and could 
be helpful in the treatment of inflammatory conditions or diseases [171]. 
Further beneficial results with P. freudenreichii JS were obtained with different randomised, 
placebo-controlled, double-blind trials in humans such as: reduction in the serum level of C-
reactive protein (an inflammation marker) [172];  induction of IL-4 and IFN-gamma 
production in PBMCs of infants with cow’s milk allergy  [173]; prevention of IgE-associated 
allergy in caesarean-delivered children [174] and increase in the resistance to respiratory 
infections during the first two years of life  [175].  
With respect to other dairy species, an increase in the phagocytic activity of peritoneal 
macrophages and the phagocytic function of the reticuloendothelial system was observed in 
mice fed with Propionibacterium acidipropionici CRL 1198 [124]. In addition, administration of 
this strain prior to infection of mice with Salmonella Typhimurium led to an increase of the 
anti-Salmonella IgA level and the number of IgA producing cells [176].  
Dairy propionibacteria may also act as safe adjuvant for development of oral vaccines. 
Adams et al [177] found that Propionibacterium jensenii 702 co-administered orally with 
soluble Mycobacterium tuberculosis antigens to mice stimulate T-cell proliferation of splenic 
lymphocytes in a significant manner so that the strain PJ702 could act as a potential living 
vaccine vector to be used against mucosal transmitted diseases. 
4.4. Gut microbial modulation 
Stimulation of bifidobacteria: It is well-documented that propionibacteria can modulate gut 
microbiota in a positive manner by enhancing bifidobacterial growth. This property has 
been demonstrated both in vitro [110, 111, 178, 179], and in vivo [127, 180-182] and the 
bifidogenic growth stimulators (BGS) involved in this effect were identified. The active 
compounds that were present in supernatants of P. freudenreichii, P. jensenii and P. 
acidipropionici were purified and identified as 2-amino-3-carboxy-1,4-naphtoquinone 
(ACNQ) [110, 178] and 1,4-dihydroxy-2-naphtoic acid (DHNA) a precursor of 
menaquinone (vitamin K2) biosynthesis [111]. It has been proposed that these compounds 
serve as electron transfer mediators for NADP regeneration in bifidobacteria [183], thus 
favoring growth. 
The bifidogenic effect of selected strains of P. freudenreichii [127, 180-182] or purified BGS 
[184] was assessed in independent studies performed on human volunteers. As a general 
result, increased fecal bifidobacterial populations were observed even after some days after 
stopping the consumption of propionibacteria. Besides a reduced colonic transit time and a 
reduction in the numbers of clostridia were evidenced in some studies. 
Inhibition of pathogens: There are several reports on the ability of dairy propionibacteria to 
inhibit exogenous and opportunistic pathogens. In vitro studies have demonstrated that P. 
freudenreichii strain JS was able to inhibit, alone or combined with other probiotics the 
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adhesion of different pathogens including H .pylori to intestinal mucus and Caco2 cell line 
also improving the epithelial barrier function [170, 185]. Other dairy species like P. 
acidipropionici strain Q4 was able to prevent the adhesion of Salmonella enteritidis and 
Escherichia coli to HT29 cells [144] whereas P. acidipropionici CRL 1198 regulates in vitro the 
growth of Bacteroides and Clostridium in cecal homogenates of mice supplemented with 
propionibacteria and/or inulin [33]. Mice consuming this strain delivered in water, milk or 
cheese showed a decrease in the number of anaerobes and coliforms in the caecal content 
one week after feeding [124, 137, 145]. P. acidipropionici CRL 1198 also prevented tissue 
colonization by Salmonella Typhimurium in mice [176].  
In humans, propionibacteria have been used in combination with Lactobacillus spp. and 
Bifidobacterium spp. in the treatment of intestinal disorders and regulation of gut flora and 
motility. It has been demonstrated that the consumption of probiotic mixtures containing 
Propionibacterium freudenreichii JS reduced oral Candida in elderly [186] and gastric 
inflammation of the mucosa caused by H.pylori in the host. [187].  Besides, infants and 
children fed with Propiono-Acido-Bifido (PAB) milk [188] or milk containing P. 
freudenreichii subsp. shermanii and L. acidophilus [189], showed a reduction in coliforms with 
an increase in lactobacilli and bifidobacteria population.  
Alleviation of IBD: It has been demonstrated that consumption of either isolated BGS or P. 
freudenreichii strains ameliorate experimental colitis in mice and human ulcerative colitis 
[171, 189-192]. The mechanism proposed for this effect was restoring of microbiota intestinal 
balance and suppressing inflammatory lymphocyte infiltration. In this respect, it has been 
proposed that some surface compounds should be involved in immunomodulatory effects 
of propionibacteria since removal of surface layer proteins decreased the in vitro induction 
of anti-inflammatory cytokines [171]. By their side, Michel et al. [193] demonstrated that 
colonic infusion with P. acidipropionici reduced the severity of TNBS induced colitis in rats 
whereas Kajander et al [194] reported that the multispecies probiotic mixture containing 
Propionibacterium freudenreichii JS was effective in alleviating irritable bowel syndrome 
symptoms. 
4.5. Modulation of the host and resident microbiota metabolism 
Lactose malabsorption: The ability of probiotics to alleviate lactose intolerance by supplying β-
galactosidase for the intraintestinal hydrolysis of lactose has been widely reported for LAB and 
bifidobacteria [196].  However there are no clinical reports on this property for dairy 
propionibacteria. Several evidences suggest the potential of Propionibacterium acidipropionici 
strains on this subject: they have high β-galactosidase activity that remain unaltered in the 
conditions of the human’s intestine, and cells are permeabilized by bile, which in turn may 
favour the hydrolysis of lactose within the intestine [131, 132]. Besides, the manufacture 
conditions of Swiss-type cheese did not decrease the synthesis and activity of the β-
galactosidase of these propionibacteria [197]. When mice were fed with P.acidipropionici CRL 
1198 included in milk or cheese, the β-galactosidase levels in the small bowel and the propionic 
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acid concentration in the caecum were significantly increased. High SCFA concentration in the 
colon could counteract diarrhea induced by non-digested carbohydrates [137].  
Hypocholesterolemic properties:  The reduction of cholesterol has been assessed for many 
probiotics with conflicting results. Somkuti and Johnson [198] evidenced the ability of P. 
freudenreichii cells to remove by surface adsorption up to 70% of the cholesterol from the 
medium, whereas Perez Chaia et al [124] demonstrated, in an animal study, that P. 
acidipropionici CRL 1198 was able to reverse the hyperlipemic effect of a diet with a high 
lipid content. However, the mechanisms underlying this beneficial effect were not 
determined in this investigation. 
Antimutagenic properties: Vorobjeva [199] demonstrated the antimutagenic activity (AM) of 
Propionibacterium freudenreichii against the mutations induced by 4-nitro-quinoline and N-
nitro-N-nitrosoguanidine (transition mutations), and by 9-aminoacridine and 2-
nitrofluorene (frame-shift mutations). This AM activity was exerted by live and dead cells 
and by the cultured media. The active compound responsible for this activity was identified 
as a cysteine synthase which is induced by some stress factors.  
Anticarcinogenic properties: Several in vitro and in vivo studies (mainly in animal models) have 
suggested the potential of probiotics to prevent have suggested the potential of probiotics to 
prevent colon cancer as evidenced by colon cancer as evidenced by a decrease in the 
incidence and magnitude of tumours and preneoplastic lesions [200]. Among the 
mechanisms involved it could be mentioned: inhibition of enzyme activities that convert 
procarcinogens into carcinogens, control of harmful bacteria, antigenotoxicity, production of 
active metabolites and immunomodulation.  
Regarding propionibacteria, it has been demonstrated that P.acidipropionici CRL1198 fed to 
mice was able to modulate the metabolism of the resident microbiota as it prevented the 
induction of azoreductase, nitroreductase and β-glucuronidase activities caused by a cooked 
red-meat supplemented diet. Furthermore, feeding with propionibacteria resulted in a 
remarkable reduction of β-glucuronidase activity and slight reductions of azo and 
nitroreductase activities [201]. In humans, independent researches have shown that 
consumption of P. freudenreichii subsp. shermanii JS decreased to different extents fecal 
azoreductase activity in elderly subjects, β-glucosidase and urease in healthy young men 
and β-glucuronidase activity of irritable bowel syndrome patients [202, 203]. 
Other studies have reported that dairy propionibacteria kill human colorectal 
adenocarcinoma cells in vitro through apoptosis via their metabolites, propionate and 
acetate [204, 205]. In addition, consumption of P. freudenreichii TL133 by human microbiota 
associated rats significantly increased the number of apoptotic cells in the colon of 1,2- 
dimethylhydrazine treated rats but have no effect on healthy colonic mucosa [77]. The 
authors suggest that dairy PAB may help in the elimination of damaged cells by apoptosis 
within the colon epithelium after genotoxic insult. Long term studies assessing the 
protective role of PAB against colon cancer are still missing. 
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4.6. A less studied mechanism: Binding of toxic compounds 
Foods daily ingested by humans and animals may possess besides nutrients, many toxins 
and antinutrititive factors that could be endogenous (i.e., compounds naturally occurring 
because of the inherent genetic characteristics of the plant or animal used as food) or 
produced by the action of microorganisms, under the influence of physical factors, or by 
chemical reactions between food constituents. Among these deleterious compounds it could 
be mentioned: trypsin inhibitors, lectins, biogenic amines, mycotoxins, etc. In this respect, 
several studies have focused, in recent years, on the ability of safe bacteria to bind and 
remove toxic compounds from different environments such as the gut and food. 
Numerous findings have shown that intestinal microorganisms and lactic acid bacteria 
ingested with food, including probiotics, play a role in detoxification of various classes of 
DNA-reactive carcinogens such as heterocyclic aromatic amines (HAs), pyrolysis products 
of amino acids contained in meat and fish products [206-209].  
Most studies have ascribed this effect to the physical binding of the mutagenic compounds 
to the bacteria rather than their metabolism. The binding of the HAs (Trp-P-2, PhIP, IQ and 
MeIQx) to bacteria is generally measured by HPLC and/or the decrease in mutagenicity in 
bacterial assays (mainly in Salmonella frameshift tester strains) and genotoxicity by comet 
assay. In attempts to elucidate the mechanisms involved in the binding of Tryptophan 
pyrolysates it was found that the structure of the cell wall plays a role in the inactivation 
and that the effect may involve cation exchange processes. Although gram-positive strains 
were more effective than gram-negative to remove HAs, these compounds bound both to 
peptidoglycan and outer membrane. Sreekumar and Hosono [209] studied the binding of 
Trp-P-1 to Lactobacillus gasseri, and postulated that the binding receptors of the HAs are the 
carbohydrate moieties of the cell walls and that glucose molecules play a key role in the 
binding reaction. By comparing, the effects of heat inactivated cells with those of living cells, 
it was suggested that living bacteria may also produce metabolites or catalyze reactions 
which lead to the detoxification of the amines [208]. However there are no reports on the 
ability of propionibacteria to detoxify HAs.  
Another detoxification property proposed for probiotics is their ability to remove 
mycotoxins. These fungal metabolites are carcinogens that unavoidable contaminate cereals 
and grains destined for human consumption. Mycotoxins are also forage contaminants, 
which impair animal performances and health. Several probiotic bacteria, commonly used in 
food products, have been shown to bind Aflatoxin B1 and the toxins produced by Fusarium 
sp such as zearalenone, fumonisins B1 and B2 and trichothecenes, like deoxynivalenol 
(DON), nivalenol (NIV) and T-2 toxin (T-2) preventing their absorption in the 
gastrointestinal tracts of animals and humans [210-214]. 
The capacity of Propionibacterium freudenreichii strain JS used alone and combined with 
lactobacilli (L. rhamnosus GG or LC705) to remove mycotoxins has been studied by in vitro 
[210-212], ex vivo [211] and in vivo assays [213-214]. It has been determined that both viable 
and heat-killed forms of propionibacteria are able to remove efficiently aflatoxin B1, 
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fumonisins and trichotecenes from liquid media. Binding, not biodegradation appeared to 
be the mode of action, as no toxin derivatives were observed and removal was not impaired 
in nonviable bacteria. Kinetics of adsorption and desorption of Aflatoxin B1 by viable and 
no viable bacteria have also been determined [215]. Tested ex vivo in the intestinal lumen of 
chicks, there was a 63% reduction in the uptake of AFB1 by the intestinal tissue in the 
presence of P.freudenreichii JS and its binding ability seems to be even better than in vitro 
results [211]. When combined with L. rhamnosus LC-705, 57-66% of AFB1 was removed by 
the probiotic mixture in vitro whereas 25% of AFB1 was bound by bacteria in ex vivo 
experiments being tissue uptake of AFB1 also reduced when probiotic bacteria were present 
in the duodenal loop [211]  
Intestinal mucus significantly reduced AFB1 binding by the probiotic mixture and vice-
versa (preincubation with AFB1 reduced mucus binding) [216]. However, similar binding 
sites are unlikely to be involved, since heat-treated bacteria lost their ability to bind 
intestinal mucus, whereas AFB1 binding was found to be enhanced by heat treatment. It has 
been proposed that proteins must be involved in the binding of mucus, whereas 
carbohydrates must bind AFB1 [217, 218]. Other mechanisms, such as steric hindrance, may 
cause interference in AFB1 and mucus binding by bacteria. These findings have relevance, 
since probiotics adhering to the intestinal wall are less likely to bind and consequently 
accumulate AFB1 in the host. On the other hand, probiotics with AFB1 bound to their 
surfaces are less likely to adhere to the intestinal wall and prolong exposure to dietary 
AFB1. Specific probiotics may be significant and safe means to reduce absorption and 
increase excretion of dietary AFB1 from the body. 
On clinical trials it has been observed that the consumption of a probiotic preparation 
containing both P. freudenreichii JS and L. rhamnosus LC-705 reduced in a significant manner 
the levels AFB1 in fecal samples [213] and the concentration of urinary AFB-N7-guanine 
[214] of healthy volunteers during treatment and even after several days after probiotic 
consumption ceased. These results suggest that the probiotic bacteria used in these trials 
could block the intestinal absorption of aflatoxin B1 
Dietary exposure to heavy metals and cyanotoxins may have detrimental effects on human 
and animal health, even at low concentrations. Specific probiotic bacteria may have 
properties that enable them to bind these toxins from food and water. In this respect, it has 
been reported that P. freudenreichii spp. shermanii JS alone and combined with other 
probiotics have the ability to remove microcystin-LR [219] and also cadmium and lead from 
aqueous solution [219, 220] and could be considered a promising microorganism for 
decontamination in food and intestinal models.  
Lectins are proteins which interact selectively and reversibly with specific residues of 
carbohydrates present in glycoconjugates [221]. Although their biological relevance as 
recognition molecules is well-known their physiological role and impact on health is 
controversial since both beneficial and deleterious effects have been ascribed to different 
lectins [222, 223]. Plant lectins are widespread in the human diet, in food items such as 
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vegetables, fruits, cereals, legumes, etc, so their ingestion could be significant [224]. They are 
also present in other members of the Leguminosae and Gramineae Families that are used as 
farm feeds.  
Most plant lectins are highly resistant to degradation by cooking and by digestive 
processes, so after consumption, they reach the intestinal lumen in a bioactive state and 
bind specifically to carbohydrate moieties expressed on the glycocalix of enterocytes 
affecting cellular physiology [221]. In general, lectins from the Leguminosae Family are 
considered as antinutritive or toxic substances since they lead to deleterious 
morphological and physiological changes after binding to the intestinal mucosa. Those 
changes include the thinning of the mucus lining, reduction of the absorptive function 
and nutrient utilization, genotoxic effects like single strand breaks in the DNA and 
stimulation of cellular proliferation and turnover that could lead to tumors development 
[225-229]. Some of these alterations could be initially unnoticed but lead to important 
nutritional deficiencies in the long term, being their impact on health of significant 
relevance.  
Different alternatives have been proposed in order to prevent or counteract the 
deleterious effects of toxic or antinutritional dietary compounds on the GIT (Figure 2), 
being of particular interest those that focus on a suitable complementary diet. Regarding 
lectins, it has been proposed that a high dietary intake of carbohydrate-containing foods, 
complementary to most toxic lectin expected in the diet, would offer protection by 
binding free lectin in the colonic lumen (Figure 2a). In this sense, it has been reported that 
the consumption of sucrose may reduce the toxic effects of legume lectins such as red 
kidney beans by protecting barrier function, bacterial overgrowth and bacterial 
translocation [230]. In the same way, it has been proposed, that a high consumption of 
galactose-containing carbohydrates, such as galactose-containing vegetable fiber, would 
offer protection against binding and proliferative effects of galactose-N-
acetylgalactosamine-binding dietary lectins (such as PNA) on colonic neoplastic 
epithelium [229, 231]. 
The same role could be played by bacteria with suitable sugar residues on their surface, 
that would reduce the interaction between dietary lectins and cells by competing for the 
sites where these molecules bind (Figure 2b), by capturing and removing free lectins 
(Figure 2c) or by binding to different receptors and blocking lectin access to their 
receptors (Figure 2d). . 
With this concept in mind, it could be proposed that probiotic microorganisms with the 
appropriate surface glycosidic moieties could be consumed as a part of human or animal 
diets to interfere with the cell-lectin recognition process preventing some toxic effects. In 
consequence, in recent years we have initiated a research line aimed to assess the capacity of 
dairy propionibacteria to protect the intestinal mucosa from the deleterious effects of dietary 
lectins.  
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Figure 2. Mechanisms proposed to counteract the interaction lectin-intestinal cell. A) Dietary 
carbohydrates complimentary to free lectin in the intestinal lumen; B) Bacterial binding analogous to 
lectin binding; C) Microorganisms that bind free lectins; D) Microorganisms that adhere to the 
epithelium blocking the binding of lectins to intestinal receptors.  
In a recent study [232], we have assessed in vitro the citotoxic effects of three plant lectins: 
concanavalin A (Con A), peanut agglutinin (PNA) and jacalin (AIL) on intestinal epithelial 
cells (IEC) of mice finding out that the three lectins used in the study induced cells death in 
a different extent. The effect was remarkable only with Con A and AIL since they reduced 
the percentage of viable cells from 88 ± 12% to 63 ± 10% and 64 ± 12% respectively after 120 
min of contact as determined by Trypan Blue dye exclusion.  
Then we evaluated the ability of different dairy propionibacteria to bind those lectins 
decreasing their citotoxic effects and the relation between bacterial adhesion to epithelial 
cells and protection against lectins. Two bacterial strains, with and without the property of 
adhesion to IEC, were studied for their ability to remove lectins from the reaction mixture. 
Both Propionibacterium acidipropionici (adh+) and P. freudenreichii (adh-) were able to remove 
60–70% of Con A and AIL as determined by the free protein detected in the interaction 
supernatants. Removal was due to binding with specific sugar moieties on the bacterial 
surfaces, as was evidenced by inhibition in the presence of sugars specific for each lectin. It 
is known that dairy propionibacteria possess residues of glucose, mannose and galactose in 
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their cell walls depending on the species [233] that would allow their interactions with 
ConA and AIL. Besides, no growth or production of SCFA was observed in a synthetic 
medium supplemented with ConA or AIL as sole carbon and energy sources confirming the 
binding hypothesis.  
When the supernatants of the interactions bacteria-lectin reaction mixtures were assayed for 
their toxic effect against IEC a great reduction on the percentages of necrotic cells was 




Viable Necrotic Apoptotic 
Control 85  6 10  7 5  2 
Con A 58  3 35  5 7  5 
P. acidipropionici + Con A 82  4 9  1 11  4 
P.freudenreichii+ Con A 89  2 5  4 6  2 
AIL 62  13 36  5 2  3 
P. acidipropionici + AIL 78 9 8  2 13  5 
P.freudenreichii+ AIL 75  5 15  2 10  1 
Table 3. Cytotoxic effects of lectins, and protection of colonic cells by lectin removal by propionibacteria. 
Control: Cells exposed to PBS. Con A and AIL: Cells exposed to 100 µg/mL of lectins; Propionibacteria+lectins: 
Supernatant of interactions bacteria-lectins after removal of bacteria. Viability was assessed by counting 
cells under the fluorescence microscope after propidium iodide ⁄ fluorescein diacetate ⁄ Hoescht staining. 
Adapted from Zárate and Pérez Chaia, J. Appl. Microbiol (2009)106: 1050-1058 [232].  
Since the cellular damage was almost completely abolished when lectin solutions were 
preincubated with bacteria it is evident that microorganisms remove these compounds from 
the media avoiding their deleterious effects on cells. 
Both strains were subjected to chemical and enzymatic treatments used to remove surface 
structures previous to their interaction with Con-A, and then were assayed for their ability 
to bind this lectin and to adhere to IEC. As shown in the Figure 3 different components are 
involved in the Con A-bacteria interaction depending on the strain studied.  
In adherent P. acidipropionici both carbohydrates and proteins seemed to be involved in 
Con A removal since high cytotoxic effects of interaction supernatants was observed 
when these surface structures were removed. In contrast, the lectin removal by a 
nonadherent strain of P. freudenreichii only depended on cell wall carbohydrates as 
periodate treatment of bacterial cells was the only responsible for the loss of protective 
effect on IEC of this strain (Figure 3a, right). Besides, in adherent P. acidipropionici  the 
lectin receptors on the bacterial surface and the adhesion determinants seem to be related, 
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since both the abilities to adhere to IEC and to remove Con A were lost after treatments 
with periodate and pronase E (Fig. 3a left and 3b). Con A bound to P. acidipropionici, 
reduced but not abolished adhesion of P. acidipropionici to IEC suggesting that 
carbohydrates other than glucose and mannose on the bacterial surface are also involved 
in the bacteria-IEC interaction (Fig. 3b) 
 
Figure 3. Influence of bacterial surface components on lectins removal (a) and adhesion property (b). (a) 
Viability of IEC exposed to the interaction supernatants of Con A and propionibacteria treated with 
chemical agents in order to remove cell surface structures. (b) Adhesion ability (%) of treated 
propionibacteria after incubation with Con A. wL: propionibacteria without lectin interaction, wb: lectin 
without bacteria; a: Non-treated bacteria; b: protease treatment (cell wall proteins remotion); c: LiCl 
treatment (S-layer); d: periodate treatment (polysaccharides); e: phenylmethylsulfonylfluoride 
treatment (lectin-like adhesins). Reproduced from: Zárate and Perez Chaia, Journal of Applied 
Microbiology (2009) 106: 1050–1057 [232]. 
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Although Con A is not a regular component of human diets, it is a good model to study 
the behaviour of members of the mannose binding lectins family, which include, among 
others, lectins found in lentils and kidney beans. However, Con-A and other lectins like 
WGA (from wheat) and SBA (from soy) could be found in feed formulations for broilers 
leading to epithelial damages and growth depression of BB chicks. In consequence, 
probiotic bacteria could be considered also by avian industry to avoid the undesirable 
effects of lectins on animal’s health by capturing them or by blocking their ligands in the 
mucosa. In this respect, it has been observed that some LAB and P. acidipropionici isolated 
from the chicken gut were able to bind Con A and WGA (Babot et al 2012 unpublished 
results) so that further studies are actually ongoing in order to develop a lectin-protector 
probiotic for broilers. 
Since the removal in vitro of Con A and AIL by dairy propionibacteria was an effective way 
to avoid the toxic effects against intestinal cells, we assessed in vivo the effects of Con A on 
some morphological and physiological parameters related to intestinal functionality such as 
small bowel architecture, main microflora components and disaccharidase activities of 
Balb/c mice after long term feeding with this lectin alone (8 mg/kg/day of Con A for 3 
weeks) or with the simultaneous consumption of Propionibacterium acidipropionici CRL 1198 
(5 x 108 CFU/mice/day) [145].  
Long-term inoculation of adult Balb/c mice with Concanavalin A resulted in a less food 
efficiency since food consumption was not affected but animals gained less weights during 
this treatment, suggesting an alteration of the digestion/absorption function of the intestine 
in the presence of lectin. Other deleterious effects observed during Con A feeding include a 
significant increase of the stomach size and transient enlargement of other organs such as 
liver, small bowel and cecum; and histomorphological and physiological alterations. In fact, an 
increased intestinal epithelial cell proliferation, evidenced by the higher cellularity of the 
epithelium lining the villus and the disarrangement and stratification of nuclei was 
observed at the optical microscopic level. At the ultrastructural level, a marked shortening 
and shedding of microvilli were evidenced in the lectin treated group as could be seen in 
Fig. 4(a) and (b). Similar results were reported previously by Lorenzsonn and Olsen [225] 
who observed in the jejunum of normal rats, an increased shedding of brush border 
membranes, acceleration of cell loss and shortening of villi as acute effects after an 
intraluminal injection of Con A. or WGA.  
The histomorphological modifications induced by Con A were greatly prevented by 
consumption of propionibacteria at the same time than Con A (Fig. 4c and 4d). By their side, 
mice that consumed P. acidipropionici CRL 1198 showed no remarkable differences with 
respect to the control animals.  
Intestinal microbial populations were also modified by lectin feeding. Mice fed Con A 
showed increased enterobacteria and enterococci populations whereas lactobacilli, 
bifidobacteria and propionibacteria were not affected. Inclusion of P. acidipropionici CRL 
1198 in the diet prevented these microbial modifications induced by Con A. 
 





Figure 4. Transmission electron microscopy photomicrographs of the microvillous surface of the small 
bowel of mice fed with Con A (Group 2) (panels a-b) and those that consumed lectin plus 
propionibacteria (Group 4) (Panels c-d). Reproduced from Zárate and Perez Chaia, Food Research 
International (2012), 47(1): 13-22 [145]. 
With respect to physiological effects, since lectins interact in the intestine with the mucosa 
membrane; it could be expected that the processes that take place at this level, such as 
hydrolysis of dietary components and nutrients transport may be affected leading to a low 
nutritional status. Besides, structural alterations could also contribute to physiological 
changes. The four dissacharidases assessed in this study were affected by Con A to some 
extent.  Daily Con-A feeding led to a significant decrease of lactase, sucrase, and trehalase 
activities whereas maltase seemed to be less affected. One week after treatments were 
finished sucrase and trehalase were still below control values. In general, consumption of 
propionibacteria with Con A resulted in activities similar to those of untreated animals and 
those fed propionibacteria alone (Figure 5).  
From the results obtained up to now it could be suggested that consumption of foods 
containing these propionibacteria would be a valuable tool for protecting the intestinal 
mucosa of humans and animals from the undesirable interactions with antinutritional 
lectins.  
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Figure 5. Effect of Concanavalin A, P.acidipropionici CRL 1198 and lectin plus  propionibacteria feeding 
on the disaccharidase activities of intestinal mucosa homogenates of Balb/c mice. G1: Control; G2: Con 
A, G3: P. acidipropionici CRL 1198, G4: Con A+ CRL 1198. Values are means  SD. The asterisk indicates 
significant differences with the control group (G1) (P<0.05). Reproduced from Zárate and Perez Chaia, 
Food Research International (2012), 47(1): 13-22 [145]. 
Although probiotic microorganisms are considered a promising alternative to physico-
chemical methods to be used as biological sequestering agents of toxins, further in vivo 
studies are needed in order to confirm that the inclusion of such microorganisms in the diet 
may reduce the absorption of deleterious compounds in the gastrointestinal tract. 
5. Concluding remarks 
From the extensive data reviewed in the present article it can be concluded that dairy 
propionibacteria are valuable microorganisms for both technological applications and health 
promotion. Although many studies have been made and the current knowledge of the 
genus has increased in different and well-defined fields further studies are needed in order 
to select the best strains and their most appropriate delivery vehicles. In this sense the 
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unique nature of the genus Propionibacterium (such as the resistance to stress and particular 
technological and probiotic properties) turns it, and particularly dairy species, as promising 
microorganisms to be incorporated in new types of food products. However, randomized, 
placebo-controlled, double blind human trials that confirm the properties of individual 
propionibacteria are still lacking. It could be expected that in the near future this void will 
be filled and new possible applications for propionibacteria will be discovered on the basis 
of newly available genome sequence and the recent development of molecular tools. 
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